HC Wainwright Has Bullish Forecast for LABT Q4 Earnings

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – Equities researchers at HC Wainwright increased their Q4 2026 earnings per share (EPS) estimates for shares of Lakewood-Amedex Biotherapeutics in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($0.21) per share for the quarter, up from their previous estimate of ($1.44). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $4.96 per share. HC Wainwright also issued estimates for Lakewood-Amedex Biotherapeutics’ FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.92) EPS.

Several other analysts have also recently issued reports on LABT. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lakewood-Amedex Biotherapeutics has an average rating of “Hold”.

Get Our Latest Report on Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Price Performance

NASDAQ LABT opened at $0.24 on Thursday. The company has a market cap of $568,800.00 and a P/E ratio of -0.05. The stock has a 50-day moving average of $0.88 and a two-hundred day moving average of $5.20. Lakewood-Amedex Biotherapeutics has a 1-year low of $0.17 and a 1-year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10).

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Recommended Stories

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.